152 related articles for article (PubMed ID: 22265843)
1. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers.
Jones MD; Young P; Traini D
Adv Drug Deliv Rev; 2012 Mar; 64(3):285-93. PubMed ID: 22265843
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
Jones MD; Buckton G
Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
[TBL] [Abstract][Full Text] [Related]
3. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
Zhou QT; Morton DA
Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
[TBL] [Abstract][Full Text] [Related]
4. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
5. Lactose characteristics and the generation of the aerosol.
Pilcer G; Wauthoz N; Amighi K
Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
[TBL] [Abstract][Full Text] [Related]
6. Physico-chemical aspects of lactose for inhalation.
Kou X; Chan LW; Steckel H; Heng PW
Adv Drug Deliv Rev; 2012 Mar; 64(3):220-32. PubMed ID: 22123598
[TBL] [Abstract][Full Text] [Related]
7. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
Donovan MJ; Smyth HD
Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
[TBL] [Abstract][Full Text] [Related]
8. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
de Boer AH; Chan HK; Price R
Adv Drug Deliv Rev; 2012 Mar; 64(3):257-74. PubMed ID: 21565232
[TBL] [Abstract][Full Text] [Related]
9. Surface Energy Determined by Inverse Gas Chromatography as a Tool to Investigate Particulate Interactions in Dry Powder Inhalers.
Das SC; Tucker IG; Stewart PJ
Curr Pharm Des; 2015; 21(27):3932-44. PubMed ID: 26290201
[TBL] [Abstract][Full Text] [Related]
10. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
11. [Effect of surface modification on surface energy of lactose and performance of dry powder inhalations].
Jiang RG; Zhang PW; Wang LQ; Liu H; Pan WS; Wang CL
Yao Xue Xue Bao; 2005 Apr; 40(4):373-6. PubMed ID: 16011271
[TBL] [Abstract][Full Text] [Related]
12. Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC.
Kumon M; Suzuki M; Kusai A; Yonemochi E; Terada K
Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1508-14. PubMed ID: 17077547
[TBL] [Abstract][Full Text] [Related]
13. Void forming index: A new parameter for detecting microstructural transformation caused by powder agglomeration.
Maruyama S; Yonemochi E; Hasegawa S; Suzuki S; Minami H
Int J Pharm; 2017 Oct; 532(1):118-123. PubMed ID: 28842308
[TBL] [Abstract][Full Text] [Related]
14. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics.
Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324
[TBL] [Abstract][Full Text] [Related]
15. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
16. Alternative carriers in dry powder inhaler formulations.
Rahimpour Y; Kouhsoltani M; Hamishehkar H
Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
[TBL] [Abstract][Full Text] [Related]
17. Influence of fines on the surface energy heterogeneity of lactose for pulmonary drug delivery.
Ho R; Muresan AS; Hebbink GA; Heng JY
Int J Pharm; 2010 Mar; 388(1-2):88-94. PubMed ID: 20038447
[TBL] [Abstract][Full Text] [Related]
18. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
19. Towards the optimisation and adaptation of dry powder inhalers.
Cui Y; Schmalfuß S; Zellnitz S; Sommerfeld M; Urbanetz N
Int J Pharm; 2014 Aug; 470(1-2):120-32. PubMed ID: 24792975
[TBL] [Abstract][Full Text] [Related]
20. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
